$Ocuphire Pharma(OCUP.US)$ It's a daily, weekly, and monthly chart.

$SoFi Technologies(SOFI.US)$
At last, it took a turn for Koyatsu.

$Ocuphire Pharma(OCUP.US)$A further increase is expected if it exceeds $2.23.

$Ocuphire Pharma(OCUP.US)$The momentum is likely to exceed the 50-day average moving line and reach the 200-day average moving line.

$Ocuphire Pharma(OCUP.US)$ 3-day increase. Can it go over $2?

$Grab Holdings(GRAB.US)$ If you look at the shareholders of this company, Uber, SoftBank, and Toyota Motor are listed at the top, but they probably own them in consideration of future potential. It's a low $3 stock now, but I'm looking forward to 10 years from now.

$Grab Holdings(GRAB.US)$
It's a must-have company for traveling!
Previously, traveling by taxi was an uneasy element of travel due to the possibility of getting involved in trouble or crime, etc., and the difficulty of communicating with drivers due to language. However, due to the existence of this company, travel in Southeast Asia has become safe and secure due to a system that shares the destination and amount with the driver in advance on the app and evaluates the driver (passenger) after boarding. As a result, it has contributed to an increase in the number of travelers and has also led to the development of Southeast Asia!
Good luck GRAB! Thanks chauffeur! 😄

$Grab Holdings(GRAB.US)$ Goto's stock price is sluggish. Now is the time to improve your position in the Indonesian market!!

$NVIDIA(NVDA.US)$
The idea (delusion?) that the 18th (Thursday) will rise in response to Taiwan TSM's financial results (good financial results) before close, raise stock prices at rough spots, receive Netflix's financial results after closing, and rise further outside of hours I'm holding it.

Novo's diabetes drug “Ozempic” shows a relationship with reduced risk of dementia
2024/7/12 19:59 JST (some excerpts)
Research at Oxford University in England showed that the diabetes drug “Ozempic” from the Danish pharmaceutical company Novo Nordisk is related to a decrease in the incidence of symptoms such as dementia. The results raised expectations about the side effects of Ozempic.
　　According to the same study, patients who took Ozempic for 1 year had a 48% lower risk of dementia compared to patients who had taken sitagliptin before, and the risk of causing cognitive impairment was lower than patients taking sitagliptin or similarly previous glipizide.